Abciximab-induced thrombocytopenia: Management of bleeding in the setting of recent coronary stents

Journal of Interventional Cardiology

Volumn 21, Issue 1, 2008, Pages 100-105

  Nowakowski, Kris ^a   Rogers, James ^a   Nelson, Gregory ^a   Gunalingam, Brendan ^a  

^a GOSFORD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ATENOLOL; CLOPIDOGREL; HEPARIN; RAMIPRIL; SIMVASTATIN; STEROID;

ACUTE STENT THROMBOSIS; ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CASE REPORT; CORONARY STENT; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HUMAN; INCIDENCE; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RECTUM HEMORRHAGE; RESTENOSIS; RESUSCITATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS;

ANTIBODIES, MONOCLONAL; FLUID THERAPY; GASTROINTESTINAL HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET TRANSFUSION; RISK FACTORS; STENTS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 38749109695     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2007.00296.x     Document Type: Article

References (20)

1. Cutlip DE, Baim DS, Ho KKL, et al. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation 2001 103 (15 1967 1971.
2. Moussa I, Di Mario C, Reimers B, et al. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: Frequency, predictors, and clinical outcome. J Am Coll Cardiol 1997 29 : 6 12.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 324 : 71 86.
4. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American heart association task force on practice guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention). J Am Coll Cardiol 2006 113 (1 156 175.
5. Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. Circulation 2007 115 : 813 818.
6. Wood S, Vega C. Stopping clopidogrel Therapy increases mortality in patients with drug-eluting stents. Medscape December 6, 2006. Available at http://www.medscape.com/viewarticle/548907.
7. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007 297 : 159 168.
8. Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997 95 : 809 813.
9. Aird WC, Mark EJ. Case 15-2002 - A 53-year-old man with a myocardial infarct and thromboses after coronary artery bypass grafting. N Engl J Med 2006 346 (20 1562 1570.
10. Aster RH, Curtis BR, Bougie DW, et al. Thrombocytopenia associated with the use of glycoprotein IIb/IIIa inhibitors: Position paper of the ISTH working group on thrombocytopenia and glycoprotein IIb/IIIa inhibitors. J Thromb Haemost 2006 4 (3 678 679.
11. Butler R, Hubner PJB. Acute severe thrombocytopenia after treatment with abciximab. Heart 2000 83 (4 e5.
12. Llevadot J, Coulter SA, Giugliano RP. A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J Thromb Thrombolysis 2000 9 (2 175 180.
13. Merlini PA, Rossi M, Menozzi A, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004 109 : 2203 2206.
14. Huxtable LM, Tafreshi MJ, Rakkar ANS. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol 2006 97 : 426 429.
15. Dunkley S, Evans S, Gaudry L, et al. Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events. Platelets 2005 16 (8 462 468.
16. Day JRS, Malik IS, Weerasinghe A, et al. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activations and aggregation: Implications for restenosis during percutaneous coronary intervention. Heart 2004 90 : 794 799.
17. Dayal S, Wilson KM, Leo L, et al. Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. Blood 2006 108 (7 2237 2243.
18. Nemeroff CB, Musselman DL. Are platelets the link between depression and ischemic heart disease? Depression as a risk factor for cardiovascular and cerebrovascular disease. Am Heart J 2000 140 (4 S57 S62.
19. Califf RM, the EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994 330 (14 956 961.
20. Shishehbor MH, Topol EJ, Mukherjee D, et al. Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era. Am J Cardiol 2006 97 (11 1585 1590.